Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery

Posted on
safety-and-biodistribution-of-intrathecal-administration-of-mesenchymal-stem-cells-(mscs)-and-neurotrophin-releasing-nanoparticles-in-a-porcine-csf-guided-delivery-model-for-amyotrophic-lateral-sclerosis-(als)-drug-discovery
Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery

References

  1. Sabatelli, M., Conte, A. & Zollino, M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin. Genet. 83, 408–416 (2013).

    Google Scholar 

  2. Deda, H. et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: A 1-year follow-up. Cytotherapy 11, 18–25 (2009).

    Google Scholar 

  3. Witzel, S. et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 79, 121–130 (2022).

    Google Scholar 

  4. Feldman, E. L. et al. Amyotrophic lateral sclerosis. Lancet 400, 1363–1380 (2022).

    Google Scholar 

  5. Wang, L. T. et al. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: Review of current clinical trials. J. Biomed. Sci. 23, 76 (2016).

    Google Scholar 

  6. Sironi, F., De Marchi, F., Mazzini, L. & Bendotti, C. Cell therapy in ALS: An update on preclinical and clinical studies. Brain Res. Bull. 194, 64–81 (2023).

    Google Scholar 

  7. Ciervo, Y. et al. Adipose-derived stem cells protect motor neurons and reduce glial activation in both in vitro and in vivo models of ALS. Mol. Ther. 21, 413–433 (2021).

    Google Scholar 

  8. Dolezalova, D. et al. Pig models of neurodegenerative disorders: Utilization in cell replacement-based preclinical safety and efficacy studies. J. Comp. Neurol. 522, 2784–2801 (2014).

    Google Scholar 

  9. Zhu, L., Li, S., Li, X. J. & Yin, P. Pathological insights from amyotrophic lateral sclerosis animal models: Comparisons, limitations, and challenges. Transl. Neurodegener. 12, 46 (2023).

    Google Scholar 

  10. Crociara, P. et al. Motor neuron degeneration, severe myopathy and TDP-43 increase in a transgenic pig model of SOD1-linked familiar ALS. Neurobiol. Dis. 124, 263–275 (2019).

    Google Scholar 

  11. Yang, H. et al. Species-dependent neuropathology in transgenic SOD1 pigs. Cell Res. 24, 464–481 (2014).

    Google Scholar 

  12. Zhang, B. et al. DL0410 attenuates oxidative stress and neuroinflammation via BDNF/TrkB/ERK/CREB and Nrf2/HO-1 activation. Int. Immunopharmacol. 86, 106729 (2020).

    Google Scholar 

  13. Ateaque, S. et al. Selective activation and down-regulation of Trk receptors by neurotrophins in human neurons co-expressing TrkB and TrkC. J. Neurochem. 161, 463–477 (2022).

    Google Scholar 

  14. The BDNF Study Group. A controlled trial of Recombinant methionyl human BDNF in ALS: the BDNF study group (Phase III). Neurology 52, 1427–1433 (1999).

    Google Scholar 

  15. Dąbkowska, M. et al. BDNF-loaded PDADMAC-heparin multilayers: A novel approach for neuroblastoma cell study. Sci. Rep. 13, 17939 (2023).

    Google Scholar 

  16. Dąbkowska, M., Kosiorowska, A. & Machaliński, B. The impact of serum protein adsorption on pegylated NT3-BDNF nanoparticles–distribution, protein release, and cytotoxicity in a human retinal pigmented epithelial cell model. Pharmaceutics 15, 2236 (2023).

    Google Scholar 

  17. Dąbkowska, M. et al. In vitro and in vivo characterization of human serum albumin-based PEGylated nanoparticles for BDNF and NT3 codelivery. Int. J. Biol. Macromol. 265, 130726 (2024).

    Google Scholar 

  18. Song, X. Y., Fan, C. X., Rahman, A. U., Choudhary, M. I. & Wang, X. P. Neuro-regeneration or repair: Cell therapy of neurological disorders as a way forward. Curr. Neuropharmacol. 22, 2272–2283 (2024).

    Google Scholar 

  19. Garbuzova-Davis, S. et al. Multiple intravenous administrations of human umbilical cord blood cells benefit in a mouse model of ALS. PLoS One 7, e31254 (2012).

    Google Scholar 

  20. Garbuzova-Davis, S. et al. Human umbilical cord blood treatment in a mouse model of ALS: Optimization of cell dose. PLoS One 3, e2494 (2008).

    Google Scholar 

  21. Terashima, T. et al. Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial migration. J. Neurosci. Res. 92, 856–869 (2014).

    Google Scholar 

  22. Goutman, S. A., Savelieff, M. G., Sakowski, S. A. & Feldman, E. L. Stem cell treatments for amyotrophic lateral sclerosis: A critical overview of early phase trials. Expert Opin. Investig. Drugs 28, 525–543 (2019).

    Google Scholar 

  23. Lunn, J. S., Sakowski, S. A. & Feldman, E. L. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: Recent advances and prospects for the future. Stem Cells 32, 1099–1109 (2014).

    Google Scholar 

  24. Atassi, N. et al. attendees of the International Workshop on Progress in Stem Cells Research for ALS/MND. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: ready for efficacy clinical trials? Cytotherapy 18, 1471–1475 (2016).

  25. Feldman, E. L. et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: Phase 1 trial outcomes. Ann. Neurol. 75, 363–373 (2014).

    Google Scholar 

  26. Kuzma-Kozakiewicz, M. et al. Intraspinal transplantation of the adipose tissue-derived regenerative cells in amyotrophic lateral sclerosis in accordance with the current experts’ recommendations: choosing optimal monitoring tools. Stem Cells Int. 4392017 (2018). (2018).

  27. Mazzini, L. et al. Results from phase I clinical trial with intraspinal injection of neural stem cells in amyotrophic lateral sclerosis: A long-term outcome. Stem Cells Transl. Med. 8, 887–897 (2019).

    Google Scholar 

  28. Barczewska, M. et al. Umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis: An original study. Stem Cell Rev. Rep. 16, 922–932 (2020).

    Google Scholar 

  29. Petrou, P., Kassis, I., Yaghmour, N. E., Ginzberg, A. & Karussis, D. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. Front. Biosci. Landmark 26, 693–706 (2021).

    Google Scholar 

  30. Riley, J. et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: A phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery 74, 77–87 (2014).

    Google Scholar 

  31. Karussis, D. et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 67, 1187–1194 (2010).

    Google Scholar 

  32. Prabhakar, S. et al. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: A pilot study. Neurol. India 60, 465–469 (2012).

    Google Scholar 

  33. Nabavi, S. M. et al. Safety, feasibility of intravenous and intrathecal injection of autologous bone marrow-derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: an open label phase I clinical trial. Cell. J. 20, 592–598 (2019).

    Google Scholar 

  34. Barczewska, M. et al. Safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy. Neural Regen. Res. 14, 313–318 (2019).

    Google Scholar 

  35. Staff, N. P. et al. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology 87, 2230–2234 (2016).

    Google Scholar 

  36. Berry, J. D. et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. Neurology 93, e2294–e2305 (2019).

    Google Scholar 

  37. Shin, S. et al. Comparative proteomic analysis of the mesenchymal stem cells secretome from adipose, bone marrow, placenta and Wharton’s jelly. Int. J. Mol. Sci. 22, 845. https://doi.org/10.3390/ijms22020845 (2021).

    Google Scholar 

  38. Oh, K. W. et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl. Med. 4, 590–597 (2015).

    Google Scholar 

  39. Cudkowicz, M. E. et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve 65, 291–302 (2022).

    Google Scholar 

  40. Kim, T. H. et al. Tracking of transplanted mesenchymal stem cells labeled with fluorescent magnetic nanoparticle in liver cirrhosis rat model with 3-T MRI. Magn. Reson. Imaging 28, 1004–1013 (2010).

    Google Scholar 

  41. Daldrup-Link, H. E. et al. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology 228, 760–767 (2003).

    Google Scholar 

  42. Kraitchman, D. L. et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107, 2290–2293 (2003).

    Google Scholar 

  43. Hauger, O. et al. W. MR evaluation of the glomerular homing of magnetically labeled mesenchymal stem cells in a rat model of nephropathy. Radiology 238, 200–210 (2006).

    Google Scholar 

  44. Markides, H. et al. Ex vivo MRI cell tracking of autologous mesenchymal stromal cells in a bovine osteochondral defect model. Stem Cell. Res. Ther. 10, 25 (2019).

    Google Scholar 

  45. Kim, T. et al. Mesoporous silica-coated Hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells. J. Am. Chem. Soc. 133, 2955–2961 (2011).

    Google Scholar 

  46. Ende, N., Weinstein, F., Chen, R. & Ende, M. Human umbilical cord blood effect on SOD mice (amyotrophic lateral sclerosis). Life Sci. 67, 53–59 (2000).

    Google Scholar 

  47. Habisch, H. J. et al. Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: limited intraparenchymal migration and survival narrows therapeutic effects. J. Neural Transm (Vienna). 114, 1395–1406 (2007).

    Google Scholar 

  48. Dąbkowska, M. et al. Electrostatic complex of neurotrophin 4 with dendrimer nanoparticles: controlled release of protein in vitro and in vivo. Int. J. Nanomed. 14, 6117–6131 (2019).

    Google Scholar 

  49. Dąbkowska, M., Adamczak, M., Barbasz, J., Cieśla, M. & Machaliński, B. Adsorption/desorption transition of recombinant human neurotrophin 4: Physicochemical characterization. Langmuir 33, 9548–9557 (2017).

    Google Scholar 

  50. Dąbkowska, M.; Adamczyk, Z.; Cieśla, M.; Adamczak, M.; Bober, J. Lysozyme Monolayers at Polymer Microparticles:Electrokinetic Characteristics and Modeling. J. Phys. Chem. C 2018, 122 (36), 20777–20788. DOI:https://doi.org/10.1021/acs.jpcc.8b04916.

Download references

Related Posts